Does Wegovy Help with Weight Loss?
Yes, Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight plus weight-related conditions like hypertension or type 2 diabetes. Clinical trials show it leads to substantial weight loss: participants lost 15-20% of body weight on average over 68 weeks, compared to 2-3% with placebo.[1][2]
How Much Weight Can You Expect to Lose?
In the STEP trials, the largest weight loss occurred in STEP 1: 15% average reduction (about 35 pounds for a 230-pound person) versus 2.4% on placebo. Results vary by dose (up to 2.4 mg weekly), diet, exercise, and adherence. About two-thirds of users lose at least 10% body weight.[1][3]
How Does Wegovy Work for Weight Loss?
It mimics GLP-1, a gut hormone that signals fullness to the brain, slows stomach emptying, and reduces appetite. Injections are weekly; effects build over months as dose ramps up from 0.25 mg.[2]
Who Qualifies and What Do Trials Show for Different Groups?
Approved for BMI ≥30, or ≥27 with comorbidities. STEP 2 trial in type 2 diabetes patients: 9.6% average loss versus 3.4% placebo. STEP 3 (with lifestyle intervention): 16% loss. Kids aged 12+ with obesity also approved based on adolescent trial data showing 16% loss.[1][4]
Common Side Effects and What Patients Report
Nausea (44%), diarrhea (30%), vomiting (24%), constipation (23%)—mostly mild, early on, and decrease over time. Rare risks include gallbladder issues, pancreatitis, or thyroid tumors (boxed warning). 7% discontinued due to GI effects in trials.[2][3]
Wegovy vs. Ozempic or Other Weight Loss Drugs
Same active ingredient as Ozempic (diabetes-focused, lower max dose 1 mg), but Wegovy is dosed higher for weight loss. Vs. older drugs like phentermine: Wegovy sustains loss longer without rebound. Mounjaro (tirzepatide) edges it in some head-to-head data (21% loss).[5]
Cost, Availability, and Supply Issues
Lists at $1,350/month without insurance; copays as low as $0-$25 with savings cards for eligible patients. Frequent shortages since 2023 due to demand; compounded versions fill gaps but FDA warns of risks.[6]
Long-Term Results and Weight Regain Risk
Year 2 extension data: users kept off ~15% with continued use. Stopping leads to ~2/3 regain within a year, so it's for ongoing management.[1][3]
Sources
[1] NEJM: STEP 1 Trial
[2] FDA Label for Wegovy
[3] Novo Nordisk STEP Program Data
[4] FDA Approval for Adolescents
[5] NEJM: SURMOUNT-1 (Mounjaro)
[6] FDA Shortage List